Actinium Pharmaceuticals (ATNM) Competitors $1.79 -0.03 (-1.65%) Closing price 04:00 PM EasternExtended Trading$1.78 -0.01 (-0.56%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATNM vs. ALMS, CTMX, SXTC, VYGR, KYTX, GNFT, DRUG, GALT, IMAB, and TLSAShould you be buying Actinium Pharmaceuticals stock or one of its competitors? The main competitors of Actinium Pharmaceuticals include Alumis (ALMS), CytomX Therapeutics (CTMX), China SXT Pharmaceuticals (SXTC), Voyager Therapeutics (VYGR), Kyverna Therapeutics (KYTX), GENFIT (GNFT), Bright Minds Biosciences (DRUG), Galectin Therapeutics (GALT), I-Mab (IMAB), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical products" industry. Actinium Pharmaceuticals vs. Its Competitors Alumis CytomX Therapeutics China SXT Pharmaceuticals Voyager Therapeutics Kyverna Therapeutics GENFIT Bright Minds Biosciences Galectin Therapeutics I-Mab Tiziana Life Sciences Alumis (NASDAQ:ALMS) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations. Do institutionals and insiders hold more shares of ALMS or ATNM? 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 40.7% of Alumis shares are owned by company insiders. Comparatively, 6.0% of Actinium Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend ALMS or ATNM? Alumis currently has a consensus price target of $19.80, suggesting a potential upside of 410.31%. Actinium Pharmaceuticals has a consensus price target of $4.00, suggesting a potential upside of 123.46%. Given Alumis' stronger consensus rating and higher possible upside, research analysts plainly believe Alumis is more favorable than Actinium Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alumis 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Actinium Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is ALMS or ATNM more profitable? Actinium Pharmaceuticals' return on equity of -100.85% beat Alumis' return on equity.Company Net Margins Return on Equity Return on Assets AlumisN/A -406.27% -107.29% Actinium Pharmaceuticals N/A -100.85%-47.89% Does the media refer more to ALMS or ATNM? In the previous week, Alumis had 6 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 7 mentions for Alumis and 1 mentions for Actinium Pharmaceuticals. Actinium Pharmaceuticals' average media sentiment score of 1.11 beat Alumis' score of 0.92 indicating that Actinium Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Actinium Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, ALMS or ATNM? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlumisN/AN/A-$294.23MN/AN/AActinium PharmaceuticalsN/AN/A-$48.82M-$1.47-1.22 SummaryAlumis beats Actinium Pharmaceuticals on 6 of the 11 factors compared between the two stocks. Get Actinium Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNM vs. The Competition Export to ExcelMetricActinium PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$55.84M$776.90M$5.70B$21.12BDividend YieldN/A4.84%4.69%3.60%P/E Ratio-1.291.1821.1927.40Price / SalesN/A25.35461.3060.38Price / CashN/A19.5636.2222.92Price / Book1.376.798.664.69Net Income-$48.82M-$4.32M$3.25B$995.51M7 Day Performance4.68%1.33%4.20%1.64%1 Month Performance8.48%3.74%10.82%5.92%1 Year PerformanceN/A8.18%34.70%11.50% Actinium Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNMActinium Pharmaceuticals2.4567 of 5 stars$1.79-1.6%$4.00+123.5%N/A$55.84MN/A-1.2930Positive NewsALMSAlumis3.2508 of 5 stars$3.60+2.3%$22.86+534.9%-69.9%$195.88MN/A0.00N/ANews CoverageAnalyst ForecastGap UpCTMXCytomX Therapeutics4.2271 of 5 stars$2.39-1.2%$5.33+123.2%+70.7%$192.68M$138.10M4.98170News CoveragePositive NewsGap UpSXTCChina SXT Pharmaceuticals1.2378 of 5 stars$1.66-5.1%N/A-82.2%$192.61M$1.93M0.0090Positive NewsGap UpVYGRVoyager Therapeutics3.8701 of 5 stars$3.43-1.7%$13.39+290.4%-62.8%$189.82M$80M-2.35100KYTXKyverna Therapeutics2.701 of 5 stars$4.39+8.9%$18.50+321.4%-52.5%$189.74M$7.03M-1.3096GNFTGENFIT2.4865 of 5 stars$3.79+3.8%$13.00+243.0%-4.0%$189.50M$76.77M0.00120Gap DownDRUGBright Minds Biosciences2.4522 of 5 stars$25.65+3.4%$83.25+224.6%+2,459.2%$180.68MN/A-71.25N/ANews CoveragePositive NewsGALTGalectin Therapeutics2.4432 of 5 stars$2.85+13.5%$6.00+110.5%+14.0%$180.38MN/A-3.969IMABI-Mab2.869 of 5 stars$2.14+0.5%$6.00+180.4%+50.4%$174.75M$3.89M0.00380Gap DownTLSATiziana Life Sciences1.2124 of 5 stars$1.48flatN/A+74.0%$172.94MN/A0.008 Related Companies and Tools Related Companies Alumis Alternatives CytomX Therapeutics Alternatives China SXT Pharmaceuticals Alternatives Voyager Therapeutics Alternatives Kyverna Therapeutics Alternatives GENFIT Alternatives Bright Minds Biosciences Alternatives Galectin Therapeutics Alternatives I-Mab Alternatives Tiziana Life Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ATNM) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinium Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
